Your browser doesn't support javascript.
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
Jagannathan, Prasanna; Andrews, Jason R; Bonilla, Hector; Hedlin, Haley; Jacobson, Karen B; Balasubramanian, Vidhya; Purington, Natasha; Kamble, Savita; de Vries, Christiaan R; Quintero, Orlando; Feng, Kent; Ley, Catherine; Winslow, Dean; Newberry, Jennifer; Edwards, Karlie; Hislop, Colin; Choong, Ingrid; Maldonado, Yvonne; Glenn, Jeffrey; Bhatt, Ami; Blish, Catherine; Wang, Taia; Khosla, Chaitan; Pinsky, Benjamin A; Desai, Manisha; Parsonnet, Julie; Singh, Upinder.
  • Jagannathan P; Department of Medicine, Stanford University, Stanford, CA, USA. prasj@stanford.edu.
  • Andrews JR; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA. prasj@stanford.edu.
  • Bonilla H; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Hedlin H; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Jacobson KB; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA.
  • Balasubramanian V; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Purington N; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA.
  • Kamble S; Quantitative Sciences Unit, Stanford University, Stanford, CA, USA.
  • de Vries CR; Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA.
  • Quintero O; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Feng K; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Ley C; Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA.
  • Winslow D; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Newberry J; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Edwards K; Department of Emergency Medicine, Stanford University, Stanford, CA, USA.
  • Hislop C; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Choong I; Department of Pediatrics, Stanford University, Stanford, CA, USA.
  • Maldonado Y; Department of Pediatrics, Stanford University, Stanford, CA, USA.
  • Glenn J; Eiger BioPharmaceuticals, Palo Alto, CA, USA.
  • Bhatt A; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Blish C; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
  • Wang T; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Khosla C; Department of Genetics, Stanford University, Stanford, CA, USA.
  • Pinsky BA; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Desai M; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Parsonnet J; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
  • Singh U; ChEM-H, Stanford University, Stanford, CA, USA.
Nat Commun ; 12(1): 1967, 2021 03 30.
Article in English | MEDLINE | ID: covidwho-1159789
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Polyethylene Glycols / Interleukins / COVID-19 Type of study: Controlled clinical trial / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22177-1

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Polyethylene Glycols / Interleukins / COVID-19 Type of study: Controlled clinical trial / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22177-1